Toronto, Ontario- (July 22, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use and…

TORONTO, CANADA, July 18, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use and…

TORONTO, CANADA, June 4, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a…

Toronto, Ontario–(Newsfile Corp. – May 2, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing medication-assisted treatments for…

TORONTO, CANADA, April 17, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a…

TORONTO, CANADA, April 03, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a…

Toronto, Canada – February 12, 2024 – Awakn Life Sciences Corp. (Cboe CA: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a…

In relation to the recently announced upcoming General Medical Counsel (“GMC”) medical practitioners tribunal into Dr. Ben Sessa. The allegations made against Dr. Sessa relate solely to Dr. Sessa’s private…

Toronto, Canada – February 5, 2024 – Awakn Life Sciences Corp. (Cboe CA: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a…

Awakn Designates Program AWKN-002 for Alcohol Use Disorders in the US Market Toronto, Canada – January 24, 2024 – Awakn Life Sciences Corp. (Cboe CA: AWKN, OTCQB: AWKNF, FSE: 954)…

Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating Disorders Also Includes Access to Phase 1 Data and Patents Filed in US and Key International Markets Toronto, Canada…

TORONTO, CANADA, December 15, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol…